ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.

Details

Serval ID
serval:BIB_90C58633C44F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
Journal
Multiple sclerosis
Author(s)
Horisberger A., Pantazou V., Cuendet G., Ribi C., Dunet V., Théaudin M.
ISSN
1477-0970 (Electronic)
ISSN-L
1352-4585
Publication state
Published
Issued date
10/2020
Peer-reviewed
Oui
Volume
26
Number
12
Pages
1599-1602
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Alemtuzumab is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. In contrast to rare cases of immune-mediated cutaneous vasculitis, systemic vasculitis after alemtuzumab has not yet been described. We report the case of a 29-year-old man with RRMS who developed fever, auricular chondritis, cutaneous vasculitis and life-threatening diffuse alveolar haemorrhage, 12 months after alemtuzumab. Antibodies to myeloperoxidase appeared 9 months after alemtuzumab and were extremely high at the time of vasculitis. Outcome was favourable after glucocorticoids, plasma exchanges and rituximab. Thus, alemtuzumab may induce life-threatening vasculitis in patients treated for RRMS.
Keywords
Alemtuzumab, multiple sclerosis
Pubmed
Web of science
Create date
27/02/2020 16:48
Last modification date
23/11/2020 7:24
Usage data